Zeo ScientifiX Inc (ZEOX)

[hotbuffcowboys]

Great Article Just Posted!

"The program has now treated 18 patients, from those displaying moderate symptoms to ICU patients with multiple organ failure and so-called long haulers with Post-COVID Syndrome. “We’re seeing good safety and efficacy data trends among all those patients,” says Dr. Mitrani.

She adds that her company is positioned to ramp up to commercial-scale production quickly, in part given the ready availability of raw materials.

"After you’ve seen a patient’s quality of life change so dramatically, getting it to the masses becomes paramount to the mission.”

“We don’t deny the potency of autologous stem cells, but we’ve also learned that an autologous approach has limitations in older patients and those with comorbidities. Those patients offer less-than-ideal environments for regeneration from autologous cells, and often they require multiple treatments to realize any positive results.”

COVID Long Haulers are the perfect storm for BPSR's therapy. Covid has substantially increased the amount of young people with lung damage (Which used to be a very small group of people). This group of young people have the best results with regenerative therapies, and now that this group of people has increased, so has the market for Zofin.

https://www.bioprocessonline.com/doc/beating-stem-cell-sourcing-exosome-production-challenges-0001